(Q35071452)

6 August 2017

1 reference

title

Clinical and virological aspects of hepatitis B co-infection in individuals infected with human immunodeficiency virus type-1. (English)

1 reference

6 August 2017

0 references

Louise Cooley

1

1 reference

PubMed ID

12600650

6 August 2017

Joseph Sasadeusz

series ordinal

2

1 reference

6 August 2017

1 February 2003

1 reference

Journal of Clinical Virology

6 August 2017

1 reference

6 August 2017

26

1 reference

6 August 2017

2

1 reference

6 August 2017

185-193

1 reference

Hepatitis B virus infection and vaccination status of high risk people in Sydney: 1982 and 1991.

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Anti-HIV and anti-HBV activity and resistance profile of 2',3'-dideoxy-3'-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Effects of lamivudine on replication of hepatitis B virus in HIV-infected men.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

YMDD-mutant HBV strain as a cause of liver failure in an HIV-infected patient

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Long-term follow-up of a randomized trial of interferon therapy for chronic hepatitis B in a predominantly homosexual male population.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

(-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Interferon therapy for chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Fibrosing cholestatic hepatitis in patient with HIV and hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Influence of prior HIV-1 infection on the development of chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Viral Clearance Without Destruction of Infected Cells During Acute HBV Infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Outcome of Hepatitis B Virus Infection in Homosexual Men and Its Relation to Prior Human Immunodeficiency Virus Infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Clinical aspects of the interactions between human immunodeficiency virus and the hepatotropic viruses

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Risks of chronicity following acute hepatitis B virus infection: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Global programme for control of hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Hepatitis B virus surface antigen and polymerase gene variants: potential virological and clinical significance

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Recombinant alpha interferon for chronic hepatitis B in anti-HIV positive patients receiving zidovudine

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Diminished responsiveness of male homosexual chronic hepatitis B virus carriers with HTLV-III antibodies to recombinant alpha-interferon

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

The global epidemiology of HIV/AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Highly active antiretroviral therapy used to treat concurrent hepatitis B and human immunodeficiency virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Reactivation of hepatitis B in patients with human immunodeficiency virus infection treated with combination antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Hepatitis in male homosexuals in Melbourne

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe dEpidémiologie Clinique de Sida en Aquitaine (GECSA)

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Hepatitis B in patients with HIV infection: relationship to AIDS and patient survival

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Potential role of lamivudine (3TC) in the clearance of chronic hepatitis B virus infection in a patient coinfected with human immunodeficiency virus type

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Association of hepatitis B surface antigen and core antibody with acquisition and manifestations of human immunodeficiency virus type 1 (HIV-1) infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Primary infection with a lamivudine-resistant hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Cytotoxic T cell responses in patients with chronic hepatitis B virus infection undergoing HBe antigen/antibody seroconversion

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900117-8

7 January 2021

10.1016/S1386-6532(02)00117-8

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12600650